Long-lasting, Pathogeneses-related Drying of Diabetic Macular Edema
Main Article Content
Abstract
Center-involved diabetic macular edema (DME) is the major cause of vision loss in the working-age population. Enduring DME might progressively injure the foveal layers with subsequent visual acuity loss. Therefore, the primary aim of DME therapy is to achieve an early, long-lasting dry macula to improve or sustain visual acuity. Current drug treatment has not achieved this aim. Diffuse DME (DDME), the most challenging DME type, is characterized by a compromised diffuse vasculature. Its pathogeneses include vitreofoveal traction and tractional epimacular membrane, as well as two newly-recognized pathogeneses: a) extrafoveal traction, the most common one, which is primarily detectable by 3D optical coherence tomography, and b) transitional-phase type, which represents the early tractional process and is detectable only ultra-structurally. Hence, all DDME eyes are apparently tractional. Consequently, treatment of naïve-treated DDME eyes by early pars plana vitrectomy has achieved long-lasting dry maculae in 92%–100% of eyes, typically in one step, and habitually associated with improved visual acuity. The surgery also naturally included the elimination of leaking microaneurysms (the "focal DME" component) when they were present. The transitional-phase type presents circumstances for attaining efficacious outcome by grid laser photocoagulation as well. Hence, DME seems to approach a curative situation. Accordingly, a revised pathogenesis-related DME classification is presented.
Keywords:
Dry diabetic macular edema, Extrafoveal traction, 3D-OCT, Curative DME, Diffuse DME, Focal DME, Pars plana vitrectomy, DME pathogenesis, DME classifications, Grid laser photocoagulation, Tractional DME, Transitional-phase DME, Vitreopapillary traction, Anti-VEGF
Article Details
How to Cite
OPHIR, Avinoam.
Long-lasting, Pathogeneses-related Drying of Diabetic Macular Edema.
Medical Research Archives, [S.l.], v. 12, n. 11, nov. 2024.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6035>. Date accessed: 12 dec. 2024.
doi: https://doi.org/10.18103/mra.v12i11.6035.
Section
Editorial
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Bourne RRA, Jonas JB, Bron AM, Cicinelli MV, Das A, Flaxman SR, et al. Prevalence and causes of vision loss in high income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2018;102(5):575–585. doi: org/ 10.1136/ bjoph thalmol- 2017- 311258.
2. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103(12):1796–1806. PMID: 2866759.
3. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32. doi: 10.1016/j.survophthal.2008.10.001.
4. Sorour OA, Levine ES, Baumal CR, Elnahry AG, Braun P, Girgis J, et al. Persistent diabetic macular edema: Definition, incidence, biomarkers and treatment methods. Surv Ophthalmol. 2023;68(2):147-174. doi: 10.1016/j.survophthal.2022.11.008.
5. Sadda SR, Campbell J, Dugel PU, Holekamp NM, Kiss S, Loewenstein A, et al. Relationship between duration and extent of edema and visual acuity outcome with ranibizumab in diabetic macular edema: A post hoc analysis of Protocol I data. Eye (Lond) 2020;34(3):480-490. doi: 10.1038/s41433-019-0522-z.
6. Sakamoto A, Nishijima K, Kita M, Oh H, Tsujikawa A, Yoshimura N. Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):(1325-1330. doi: 10.1007/s00417-009-1107-5.
7. Cennamo G, Montorio D, Fossataro F, Fossataro C, Tranfa F. Evaluation of vessel density in disorganization of retinal inner layers after resolved diabetic macular edema using optical coherence tomography. PLoS One. 2021;16(1):e0244789. doi: 10.1371/journal.pone.0244789.
8. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerenda BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222. doi: 10.1159/000458539.
9. The DRCR.net, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077. doi:10.1016/j.ophtha.2010.02.031
10. Elman MJ,Bressler NM,Qin H,beck RW, Ferris 3rd FL, Fridman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609-614. doi: 10.1016/j.ophtha.2010.12.033.
11. MitchellP,BandelloF,Schmidt-ErfurthU, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE Study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4): 615-625. doi: 10.1016/j.ophtha.2011.01.031.
12. Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New Eng J Med. 2015;372(13):1193-1203. doi: 10.1056/NEJMoa1414264.
13. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351-1359. doi: 10.1016/j.ophtha.2016.02.022.
14. Glassman AR, Wells III JA, Josic K, maguire MG, Antoszyk AN, Baker C, et al. Five-year outcomes after initial Aflibercept, Bevacizumab, or Ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology. 2020;127(9):1201-1210. doi: 10.1016/j.ophtha.2020.03.021.
15. La Haij EC, Hendrikse F, Kessels AGH, Derhaag PJ. Vitrectomy results in diabetic macular edema without evident vitreomacular traction. Graefe’s Arch Clin Exp Ophthalmol. 2001;239(4):264-270. doi: 10.1007/s004170000251.
16. Yanyali A, Nohutcu AF, Horozoglu F, Celik E. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol.2005;139(5):795-801. doi: 10.1016/j.ajo.2004.12.017.
17. Iglicki M, Lavaque A, Ozimek M, Negri HP, Okada M, Chhablani J, et al. Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naïve diabetic macular edema: The VITAL Study. PloS One. 2018:13(7):e0200365. doi: 10.1371/journal.pone.0200365.
18. Michalewska Z, Stewart MW, Landers III MB, Bednarski M, Adelman RA, Nawrocki J. Vitrectomy in the management of diabetic macular edema in treatment-naïve patients. Can J Ophthalmol. 2018;53(4): 402-407. doi: 10.1016/j.jcjo.2017.10.011.
19. Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, et al. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. New Engl J Med. 2022; 387(8):692-703. doi: 10.1056/NEJMoa2204225.
20. Zhang J, Wang M, Chen L, Radke N. Diabetic blindness remains a big challenge despite all recent advancements in diagnostics and treatments. Asia Pac J Ophthalmol. 2024;13(5):100105. doi: 10.1016/j.apjo/2024/100105.
21. Jorge EC, Jorge EN, Botelho M, Farat JG, Virgili G, Dib REI. Monotherapy laser photocoagulation for diabetic macular oedema. Cochrane Database of Systematic Reviews. 2018;10(10):CD010859. doi: 10.1002/14651858.CD010859.pub2
22. LadasID, TheodossiadisGP. Long-term effectiveness of modified grid laser photocoagulation for diffuse diabetic macular edema. Acta Ophthalmologica. 1993;71(3):393-397. doi: 10.1111/j.1755-3768.1993.tb07154.x.
23. Arevalo JF, Lasave AF, Wu L, Diaz-Llopis M, Gallego-Pinazo R, Alezzandrini AA, et al. Pan-American Collaborative Retina Study Group (PACORES). Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema. Retina. 2013;33(2):403-413. doi: 10.1097/IAE.0b013e3182695b83.
24. Ophir A, Martinez MR, Mosqueda P, Trevino A. Vitreous traction and epiretinal membranes in diabetic macular edema using spectral-domain optical coherence tomography. Eye (London). 2010;24(10):1545-1553. doi: 10.1038/eye.2010.80.
25. Ophir A. Full-field 3-D optical coherence tomography imaging and treatment decision in diffuse diabetic macular edema. Letter. Invest Ophthalmol Vis Sci. 2014;55(5):3052-3053. doi: 10.1167/iovs.14-14414.
26. Thi A, Freund KB, Engelbert M. A pixel-based machine-learning model for three-dimensional reconstruction of vitreous anatomy. Trans Vis Sci Technol. 2022;11(7):1-10. doi:10.1167/tvst.11.7.3
27. Spaide RF, Valmaggia P, Maloca P, Scholl HPN, Otto TP, Caujolle S. Imaging the vitreous with a novel boosted optical coherence tomography technique: vitreous degeneration and cisterns. Retina. 2022;42(8):1433–1441. doi:10.1097/IAE.0000000000003474.
28. Ohno-MatsuiK,TakahashiH,MaoZ, Nakao N. Determining posterior vitreous structure by analysis of images obtained by AI-based 3D segmentation and ultra widefield optical coherence tomography. Br J Ophthalmol.2023;107(5):732-737.doi:10.1136/bjophthalmol-2021-320131.
29. Nguyen TX, Jiang M, Yang D, Ran A, Ziqi T, Zhang S, et al. Advancing diabetic macular edema detection from 3D optical coherence tomography scans: Integrating privacy-preserving AI and generalizability techniques – a prospective validation in Vietnam. New Eng J Med. AI 2024;1(9). doi: 10/1056/Aloa2400091.
30. Ophir A, Trevino A, Fatum S. Extrafoveal vitreous traction associated with diabetic diffuse macular oedema. Eye (Lond). 2010;24(2):347-353. doi: 10.1038/eye.2009.106.
31. Ophir A. Achieving durable dry macula in diffuse diabetic macular edema: a meta-analysis. Acta Sci Ophthalmol. 2021;4.3:91-104. https://actascientific.com > ASOP-04-0225.
32. Ophir A. Re: Mylonas G, et al. The impact of the vitreomacular interface on functional and anatomical outcomes in diabetic macular edema treated with three different anti-VEGF agents: Post hoc analysis of the protocol T study. Correspondence. Retina. 2023;43(7):e39-41. doi:10.1097/IAE.0000000000003803.
33. Ophir A. Diabetic macular edema: Approaching a curative situation. Editorial. Acta Sci Ophthalmol. 2024;7.6:01-05. https://actascientific.com › ASOP › ASOP-07-0767.
34. Karatas M, Ramirez JA, Ophir A. Diabetic vitreopapillary traction and macular edema. Eye (London). 2005;19(6):676-682. doi:10.1038/sj.eye.6701622.
35. Kakehashi A, Schepens CL, de Sousa-Neto A, Jalkh AE, Trempe CL. Biomicroscopic findings of posterior vitreoschisis . Ophthalmic Surg. 1993;24(12):846-850. PMID: 8115102.
36. Sebag J. “Vitreoschisis”. Graefes Arch Clin Exp Ophthalmol. 2008;246(3):329-332. https://doi.org/10.1007/s00417-007-0743-x.
37. Ophir A, Martinez MR. Epiretinal membranes and incomplete posterior vitreous detachment in diabetic macular edema, detected by spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52(9):6414-6420. doi:https://doi.org/10.1167/iovs.10-6781
38. Adhi M, Badaro E, Liu JJ, Kraus MF, Baumal CR, Witkin AJ, et al. Three-dimensional enhanced imaging of vitreoretinal interface in diabetic retinopathy using swept-source optical coherence tomography. Am J Ophthalmol. 2016;162:140-149.e1. doi:10.1016/j.ajo.2015.10.025
39. Fatima N, Islam QU, Shafique M. Frequency of vitreomacular traction in diabetic macular edema on optical coherence tomography. Pak Armed Forces Med J. 2017;67(1):47-50. ISSN 0030-9648.
40. Martinez MR, Ophir A. Extrafoveal traction in retinal vein occlusion using spectral domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2011;249(6):811-820. doi: 10.1007/s00417-011-1666-0.
41. Krebs I, Glittenberg C, Zeiler F, Binder S. Spectral domain optical coherence tomography for higher precision in the evaluation of vitreoretinal adhesions in exudative age-related macular degeneration. Br J of Ophthalmol. 2011;95(10):1415-1418. https://doi.org/10.1136/bjo.2010.192385.
42. Ota-Itadani M, Takahashi H, Mao Z, Igarashi-Yokoi T, Yoshida T, Ohno-Matsui K. Deep learning-based 3D OCT imaging for detection of lamina cribrosa defects in eyes with high myopia. Sci Rep. 2022;12(1):22195. doi: 10.1038/s41598-022-26520-4.
43. Stanga PE, Pastor-Idoate S, Reinstein U, Vatas P, Patel U, Dubovy S, et al. Navigated single-capture 3D and cross-sectional wide-field OCT of the mid and peripheral retina and vitreoretinal interface. Eur J Ophthalmol. 2022;32(3):1642-1651. doi: 10.1177/11206721211026100.
44. Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20(2):126-133.
45. Matsunaga N, Ozeki H, Hirabayashi Y, Shimada S, Ogura Y. Histopathologic evaluation of the internal limiting membrane surgically excised from eyes with diabetic maculopathy. Retina. 2005;25(3):311–316.
https://doi.org/10.1097/00006982-200504000-00010.
46. Hagenau F, Vogt D,Ziada J,Guenther S, Haritoglou, Wolf A, et al. Vitrectomy for diabetic macular edema: Optical coherence tomography criteria and pathology of the vitreomacular interface. Am J Ophthalmol. 2019 Apr;200:34-46. doi: 10.1016/j.ajo.2018.12.004.
47. SchumannRG,Hagenau F,Guenther SR,WOLF A, Priglinger SG, Vogt D. Premacular cell proliferation profiles in tangential traction vitreo-maculopathies suggest a key role for hyalocytes. Ophthalmologica 2019;242(2):106-112. doi:10.1159/000495853.
48. Jones CH, Gui W, Schumann RG, Boneva S, Lange CA, van Overdam K, et al. Hyalocytes in proliferative vitreoretinal diseases. Expert Rev Ophthalmol. 2022;17(4):263-280. doi: 10.1080/17469899.2022.2100764.
49. Sensoy E, Citirik M. Current biosimilar anti-VEGF drugs in retinal diseases. Eur Eye Res. 2024;4:00-00. Ahead of Print: EER-29291. doi: 10.14744/eer.2024.29291.
50. Bressler SB, Barve A, Ganapathi PC, Beckmann K, Apte RS, Marcus DM, et al. Aflibercept biosimilar MYL-1701P vs. reference aflibercept in diabetic macular edema: The INSIGHT randomized clinical trial. Jama Ophthalmol. 2024:142(10):952-960. doi: 10.1001/jamaophthalmol.2024.3458.
51. Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomized, double-masked, phase 3 trials. Lancet. 2022;399(10326);741-755. doi: 10.1016/S0140-6736(22)00018-6.
52. Yoon D, Rusu I, Barbazetto I. Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities. Int Ophthalmol. 2014;34(4):817-823. doi: 10.1007/s10792-013-9884-6.
53. Russo A, Longo A, Avitabile V, Bonfiglio V, Fallico M, Boscia F, et al. Incidence and risk factors for traction macular detachment after anti-vascular endothelial growth factor agent pretreatment before vitrectomy for complicated proliferative diabetic retinopathy. J Clin Med. 2019;8(11):1960. doi:10.3390/jcm8111960.
54. Patil NS, Dhoot AS, Popovic MM, Kertes PJ, Muni RH. Risk of intraocular inflammation after injection of anti-vascular endothelial growth factor agents. Retina. 2022;42(11): 2134-2142. doi: 10.1097/IAE.0000000000003582.
55. Gopalakrishnan N, Joshi A, Yadav NK, Prabhu V, Bevaskar S, Ccablani J, et al. Progression of macular retinoschisis following intravitreal aflibercept injection for myopic macular neovascularization- a case report and review of literature. BMC Ophthalmol. 2024;24(1):224. doi: 10.1186/s12886-024-03497-4.
56. Ophir A, Hanna R, Martinez MR. Importance of 3-D image reconstruction of spectral-domain OCT on outcome of grid laser photocoagulation for diffuse diabetic macular edema. Int J Ophthalmol. 2013;6(6):836-843. doi: 10.3980/j.issn.2222-3959.2013.06.17.
57. Stefansson E,Landers, MB 3rd,Wolbarst ML. Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Trans Am Ophthalmol Soc. 1981;79:307-334. PMID: 7200671; PMCID: PMC1312190.
58. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campochiaro PA. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci. 2004;45(2):617–624. doi: 10.1167/iovs.03-0557.
59. Kroll P, Wiegand W, Schmidt J. Vitreopapillary traction in proliferative diabetic vitreoretinopathy. Br J Ophthalmol. 1999;83(3):261-264. doi: 10.1136/bjo.83.3.261.
60. Kashani AH, Zhang Y, Capone A Jr, Drenser KA, Puliafito C, Moshfeghi AA, et al. Impaired retinal perfusion resulting from vitreoretinal traction: A mechanism of retinal vascular insufficiency. Ophthalmol Surg Lasers Imaging Retina. 2016;47(3):1-11. doi: 10.3928/23258160-20160229-03.
61. Adelman R,Parnes AMichalewska Z, Parolini B, Boscher C, Ducournau D. Strategy for the Management of Diabetic Macular Edema: The European Vitreo-Retinal Society Macular Edema Study. BioMed Res Internat. 2015;Article ID352487, http://doi.org/10.1155/2015/352487
62. Browning DJ, Lee C, Stewart MW, Landers III MB. Vitrectomy for center-involved diabetic macular edema. Clin Ophthalmol. 2016 Apr 26;10:735-742. doi: 10.2147/OPTH.S104906
63. Miyamoto N, Ishida K, Ghassemi YK. Restoration of photoreceptor outer segments up to 24 months after pars plana vitrectomy in patients with diabetic macular edema. Ophthalmol Retina. 2017;1(5):389-394.doi.org/10.1016/j.oret.2017.01.017.
64. Kim JH, Kang SW, Ha HS, Kim JR. Vitrectomy combined with intravitreal triamcinolone acetonide injection and macular laser photocoagulation for nontractional diabetic macular edema. Korean J Ophthalmol. 2013;27(3):186-193. http://dx.doi.org/10.3341/kjo.2013.27.3.18661.
65. Hwang S, Kang SW, Kim KT, Noh H, Kim SJ. Three‑year outcomes of vitrectomy combined with intraoperative dexamethasone implantation for non‑tractional refractory diabetic macular edema. Sci Rep. 2021;11(1):1292. https://doi.org/10.1038/s41598-020-80350-w.
66. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99(5):753-759. doi: 10.1016/s0161-6420(92)31901-3.
67. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol. 1996;122(2):258-260. Doi: 10.1016/s0002-9394(14)72018-5.
68. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol. 2000;130(2):178-186. doi: 10.1016/s0002-9394(00)00472-4.
69. Yanyali A, Horozoglu F, Celik E, Ercalik Y, Nohutcu A. Pars plana vitrectomy and removal of the internal limiting membrane in diabetic macular edema unresponsive to grid laser photocoagulation. Eur J Ophthalmol. 2006;16(4):573-581. doi:10.1177/112067210601600412.
70. Landers MB III, Kon Graversen VA, Stewart MW. Early vitrectomy for DME: What makes it a viable treatment? Retinal Physician. 2013;10:56-60.
71. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PA, Beck RW, Bressler NM, et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research network. Retina. 2010;30(9):1488-1495. doi:10.1097/IAE.0b013e3181e7974f.
72. Zhou H, Zhang J , Guo B, Lin J, Mei J, Deng C, et al. Effect of anti-VEGF on early-stage post-vitrectomy macular edema in patients with proliferative diabetic retinopathy. BMC Ophthalmol. 2024;24(1):398. doi: 10.1186/s12886-024-03634-z.
73. Liao M, Huang Y, Wang J, Meng X, Liu Y, Yu J, et al. Long-term outcomes of administration of intravitreal triamcinolone acetonide after posterior vitreous detachment during pars plana vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol. 2023;107(4):560-564. doi: 10.1136/bjophthalmol-2021-320332.
74. Kim J, Kang SW, Shin DH, Kim SJ, Cho GE. Macular ischemia and outcome of vitrectomy for diabetic macular edema. Jpn J Ophthalmol. 2015;59(5):295-304. doi: 10.1007/s10384-015-0402-4.
75. Hatano M, Higashijima F, Yoshimoto T, Ogata T, Ohta M, Kobayashi Y, et al. Evaluation of microaneurysms as predictors of therapeutic response to anti-VEGF therapy in patients with DME. Plos One. 2022;17(11):e0277920. doi:10.1371/journal.pone.0277920.
76. Watanabe A, Takashima H, Nakano T. Effect of microaneurysms on anti-VEGF treatment for diabetic macular edema: A retrospective cross-sectional study. Medicine (Baltimore). 2023;102(44):e35888. doi:10.1097/MD.000000000000035888.
77. Nozaki M, Kato A, Yasukawa T, Suzuki K, Yoshida M, Ogura Y. Indocyanine green angiography-guided focal navigated laser photocoagulation for diabetic macular edema. Jpn J Ophthalmol. 2019;63(3):243–254. doi: 10.1007/s10384-019-00662-x.
78. Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol. 2009;93(10):1341–1344. doi: 10.1136/bjo.2008.146712.
79. Tanaka H, Kojima K, Miyatani T, Kusada N, Terao N, Nagata K, et al. A new surgical approach for the treatment of a refractory foveal microaneurysm: A case report. Am J Ophthalmol Case Rep. 2024 Mar 1;34:102034. doi:10.1016/j.ajoc.2024.102034.
80. Takamura Y, Yamada Y, Morioka M, Gozawa M, Matsumura T, Inatani M. Turnover of Microaneurysms after intravitreal injections of faricimab for diabetic macular edema. Invest Ophthalmol Vis Sci. 2023 Oct 3;64(13):31. doi: 10.1167/iovs.64.13.31.
81. Rush RB. One year results of faricimab for aflibercept-resistant diabetic macular edema. Clin Ophthalmol 2023 Aug 16;17:2397-2403. Doi: 10.2147/OPTH.S424314.
82. Takamura Y, Yamada Y, Inatani M. Role of microaneurysms in the pathogenesis and therapy of diabetic macular edema: A descriptive review. Medicina (Kaunas). 2023;59(3):435. doi: 10/3390/medicina59030435
83. Sawa M, Nakagawa N, Shunto T, Nishiyama I. Two cases of diabetic macular edema with diminished areas of retinal non-perfusion and microaneurysms after intravitreal faricimab injections. Am J Ophthalmol Case Rep. 2023 Dec 7;4;33:101973. doi: 10.1016/j.ajoc.2023.101973.
84. Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU. Diabetic macular edema: What is focal and what is diffuse? Am J Ophthalmol. 2008;146(5):649–655. doi: 10.1016/j.ajo.2008.07.013.
85. Yamada Y, Suzuma K, Ryu M, Tsuiki E, Fujikawa A, Kitaoka T. Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling. Curr Eye Res. 2013;38(12):1261-1265. doi: 10.3109/02713683.2013.820327?
2. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103(12):1796–1806. PMID: 2866759.
3. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32. doi: 10.1016/j.survophthal.2008.10.001.
4. Sorour OA, Levine ES, Baumal CR, Elnahry AG, Braun P, Girgis J, et al. Persistent diabetic macular edema: Definition, incidence, biomarkers and treatment methods. Surv Ophthalmol. 2023;68(2):147-174. doi: 10.1016/j.survophthal.2022.11.008.
5. Sadda SR, Campbell J, Dugel PU, Holekamp NM, Kiss S, Loewenstein A, et al. Relationship between duration and extent of edema and visual acuity outcome with ranibizumab in diabetic macular edema: A post hoc analysis of Protocol I data. Eye (Lond) 2020;34(3):480-490. doi: 10.1038/s41433-019-0522-z.
6. Sakamoto A, Nishijima K, Kita M, Oh H, Tsujikawa A, Yoshimura N. Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):(1325-1330. doi: 10.1007/s00417-009-1107-5.
7. Cennamo G, Montorio D, Fossataro F, Fossataro C, Tranfa F. Evaluation of vessel density in disorganization of retinal inner layers after resolved diabetic macular edema using optical coherence tomography. PLoS One. 2021;16(1):e0244789. doi: 10.1371/journal.pone.0244789.
8. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerenda BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222. doi: 10.1159/000458539.
9. The DRCR.net, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077. doi:10.1016/j.ophtha.2010.02.031
10. Elman MJ,Bressler NM,Qin H,beck RW, Ferris 3rd FL, Fridman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609-614. doi: 10.1016/j.ophtha.2010.12.033.
11. MitchellP,BandelloF,Schmidt-ErfurthU, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE Study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4): 615-625. doi: 10.1016/j.ophtha.2011.01.031.
12. Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New Eng J Med. 2015;372(13):1193-1203. doi: 10.1056/NEJMoa1414264.
13. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351-1359. doi: 10.1016/j.ophtha.2016.02.022.
14. Glassman AR, Wells III JA, Josic K, maguire MG, Antoszyk AN, Baker C, et al. Five-year outcomes after initial Aflibercept, Bevacizumab, or Ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology. 2020;127(9):1201-1210. doi: 10.1016/j.ophtha.2020.03.021.
15. La Haij EC, Hendrikse F, Kessels AGH, Derhaag PJ. Vitrectomy results in diabetic macular edema without evident vitreomacular traction. Graefe’s Arch Clin Exp Ophthalmol. 2001;239(4):264-270. doi: 10.1007/s004170000251.
16. Yanyali A, Nohutcu AF, Horozoglu F, Celik E. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol.2005;139(5):795-801. doi: 10.1016/j.ajo.2004.12.017.
17. Iglicki M, Lavaque A, Ozimek M, Negri HP, Okada M, Chhablani J, et al. Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naïve diabetic macular edema: The VITAL Study. PloS One. 2018:13(7):e0200365. doi: 10.1371/journal.pone.0200365.
18. Michalewska Z, Stewart MW, Landers III MB, Bednarski M, Adelman RA, Nawrocki J. Vitrectomy in the management of diabetic macular edema in treatment-naïve patients. Can J Ophthalmol. 2018;53(4): 402-407. doi: 10.1016/j.jcjo.2017.10.011.
19. Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, et al. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. New Engl J Med. 2022; 387(8):692-703. doi: 10.1056/NEJMoa2204225.
20. Zhang J, Wang M, Chen L, Radke N. Diabetic blindness remains a big challenge despite all recent advancements in diagnostics and treatments. Asia Pac J Ophthalmol. 2024;13(5):100105. doi: 10.1016/j.apjo/2024/100105.
21. Jorge EC, Jorge EN, Botelho M, Farat JG, Virgili G, Dib REI. Monotherapy laser photocoagulation for diabetic macular oedema. Cochrane Database of Systematic Reviews. 2018;10(10):CD010859. doi: 10.1002/14651858.CD010859.pub2
22. LadasID, TheodossiadisGP. Long-term effectiveness of modified grid laser photocoagulation for diffuse diabetic macular edema. Acta Ophthalmologica. 1993;71(3):393-397. doi: 10.1111/j.1755-3768.1993.tb07154.x.
23. Arevalo JF, Lasave AF, Wu L, Diaz-Llopis M, Gallego-Pinazo R, Alezzandrini AA, et al. Pan-American Collaborative Retina Study Group (PACORES). Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema. Retina. 2013;33(2):403-413. doi: 10.1097/IAE.0b013e3182695b83.
24. Ophir A, Martinez MR, Mosqueda P, Trevino A. Vitreous traction and epiretinal membranes in diabetic macular edema using spectral-domain optical coherence tomography. Eye (London). 2010;24(10):1545-1553. doi: 10.1038/eye.2010.80.
25. Ophir A. Full-field 3-D optical coherence tomography imaging and treatment decision in diffuse diabetic macular edema. Letter. Invest Ophthalmol Vis Sci. 2014;55(5):3052-3053. doi: 10.1167/iovs.14-14414.
26. Thi A, Freund KB, Engelbert M. A pixel-based machine-learning model for three-dimensional reconstruction of vitreous anatomy. Trans Vis Sci Technol. 2022;11(7):1-10. doi:10.1167/tvst.11.7.3
27. Spaide RF, Valmaggia P, Maloca P, Scholl HPN, Otto TP, Caujolle S. Imaging the vitreous with a novel boosted optical coherence tomography technique: vitreous degeneration and cisterns. Retina. 2022;42(8):1433–1441. doi:10.1097/IAE.0000000000003474.
28. Ohno-MatsuiK,TakahashiH,MaoZ, Nakao N. Determining posterior vitreous structure by analysis of images obtained by AI-based 3D segmentation and ultra widefield optical coherence tomography. Br J Ophthalmol.2023;107(5):732-737.doi:10.1136/bjophthalmol-2021-320131.
29. Nguyen TX, Jiang M, Yang D, Ran A, Ziqi T, Zhang S, et al. Advancing diabetic macular edema detection from 3D optical coherence tomography scans: Integrating privacy-preserving AI and generalizability techniques – a prospective validation in Vietnam. New Eng J Med. AI 2024;1(9). doi: 10/1056/Aloa2400091.
30. Ophir A, Trevino A, Fatum S. Extrafoveal vitreous traction associated with diabetic diffuse macular oedema. Eye (Lond). 2010;24(2):347-353. doi: 10.1038/eye.2009.106.
31. Ophir A. Achieving durable dry macula in diffuse diabetic macular edema: a meta-analysis. Acta Sci Ophthalmol. 2021;4.3:91-104. https://actascientific.com > ASOP-04-0225.
32. Ophir A. Re: Mylonas G, et al. The impact of the vitreomacular interface on functional and anatomical outcomes in diabetic macular edema treated with three different anti-VEGF agents: Post hoc analysis of the protocol T study. Correspondence. Retina. 2023;43(7):e39-41. doi:10.1097/IAE.0000000000003803.
33. Ophir A. Diabetic macular edema: Approaching a curative situation. Editorial. Acta Sci Ophthalmol. 2024;7.6:01-05. https://actascientific.com › ASOP › ASOP-07-0767.
34. Karatas M, Ramirez JA, Ophir A. Diabetic vitreopapillary traction and macular edema. Eye (London). 2005;19(6):676-682. doi:10.1038/sj.eye.6701622.
35. Kakehashi A, Schepens CL, de Sousa-Neto A, Jalkh AE, Trempe CL. Biomicroscopic findings of posterior vitreoschisis . Ophthalmic Surg. 1993;24(12):846-850. PMID: 8115102.
36. Sebag J. “Vitreoschisis”. Graefes Arch Clin Exp Ophthalmol. 2008;246(3):329-332. https://doi.org/10.1007/s00417-007-0743-x.
37. Ophir A, Martinez MR. Epiretinal membranes and incomplete posterior vitreous detachment in diabetic macular edema, detected by spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52(9):6414-6420. doi:https://doi.org/10.1167/iovs.10-6781
38. Adhi M, Badaro E, Liu JJ, Kraus MF, Baumal CR, Witkin AJ, et al. Three-dimensional enhanced imaging of vitreoretinal interface in diabetic retinopathy using swept-source optical coherence tomography. Am J Ophthalmol. 2016;162:140-149.e1. doi:10.1016/j.ajo.2015.10.025
39. Fatima N, Islam QU, Shafique M. Frequency of vitreomacular traction in diabetic macular edema on optical coherence tomography. Pak Armed Forces Med J. 2017;67(1):47-50. ISSN 0030-9648.
40. Martinez MR, Ophir A. Extrafoveal traction in retinal vein occlusion using spectral domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2011;249(6):811-820. doi: 10.1007/s00417-011-1666-0.
41. Krebs I, Glittenberg C, Zeiler F, Binder S. Spectral domain optical coherence tomography for higher precision in the evaluation of vitreoretinal adhesions in exudative age-related macular degeneration. Br J of Ophthalmol. 2011;95(10):1415-1418. https://doi.org/10.1136/bjo.2010.192385.
42. Ota-Itadani M, Takahashi H, Mao Z, Igarashi-Yokoi T, Yoshida T, Ohno-Matsui K. Deep learning-based 3D OCT imaging for detection of lamina cribrosa defects in eyes with high myopia. Sci Rep. 2022;12(1):22195. doi: 10.1038/s41598-022-26520-4.
43. Stanga PE, Pastor-Idoate S, Reinstein U, Vatas P, Patel U, Dubovy S, et al. Navigated single-capture 3D and cross-sectional wide-field OCT of the mid and peripheral retina and vitreoretinal interface. Eur J Ophthalmol. 2022;32(3):1642-1651. doi: 10.1177/11206721211026100.
44. Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20(2):126-133.
45. Matsunaga N, Ozeki H, Hirabayashi Y, Shimada S, Ogura Y. Histopathologic evaluation of the internal limiting membrane surgically excised from eyes with diabetic maculopathy. Retina. 2005;25(3):311–316.
https://doi.org/10.1097/00006982-200504000-00010.
46. Hagenau F, Vogt D,Ziada J,Guenther S, Haritoglou, Wolf A, et al. Vitrectomy for diabetic macular edema: Optical coherence tomography criteria and pathology of the vitreomacular interface. Am J Ophthalmol. 2019 Apr;200:34-46. doi: 10.1016/j.ajo.2018.12.004.
47. SchumannRG,Hagenau F,Guenther SR,WOLF A, Priglinger SG, Vogt D. Premacular cell proliferation profiles in tangential traction vitreo-maculopathies suggest a key role for hyalocytes. Ophthalmologica 2019;242(2):106-112. doi:10.1159/000495853.
48. Jones CH, Gui W, Schumann RG, Boneva S, Lange CA, van Overdam K, et al. Hyalocytes in proliferative vitreoretinal diseases. Expert Rev Ophthalmol. 2022;17(4):263-280. doi: 10.1080/17469899.2022.2100764.
49. Sensoy E, Citirik M. Current biosimilar anti-VEGF drugs in retinal diseases. Eur Eye Res. 2024;4:00-00. Ahead of Print: EER-29291. doi: 10.14744/eer.2024.29291.
50. Bressler SB, Barve A, Ganapathi PC, Beckmann K, Apte RS, Marcus DM, et al. Aflibercept biosimilar MYL-1701P vs. reference aflibercept in diabetic macular edema: The INSIGHT randomized clinical trial. Jama Ophthalmol. 2024:142(10):952-960. doi: 10.1001/jamaophthalmol.2024.3458.
51. Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomized, double-masked, phase 3 trials. Lancet. 2022;399(10326);741-755. doi: 10.1016/S0140-6736(22)00018-6.
52. Yoon D, Rusu I, Barbazetto I. Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities. Int Ophthalmol. 2014;34(4):817-823. doi: 10.1007/s10792-013-9884-6.
53. Russo A, Longo A, Avitabile V, Bonfiglio V, Fallico M, Boscia F, et al. Incidence and risk factors for traction macular detachment after anti-vascular endothelial growth factor agent pretreatment before vitrectomy for complicated proliferative diabetic retinopathy. J Clin Med. 2019;8(11):1960. doi:10.3390/jcm8111960.
54. Patil NS, Dhoot AS, Popovic MM, Kertes PJ, Muni RH. Risk of intraocular inflammation after injection of anti-vascular endothelial growth factor agents. Retina. 2022;42(11): 2134-2142. doi: 10.1097/IAE.0000000000003582.
55. Gopalakrishnan N, Joshi A, Yadav NK, Prabhu V, Bevaskar S, Ccablani J, et al. Progression of macular retinoschisis following intravitreal aflibercept injection for myopic macular neovascularization- a case report and review of literature. BMC Ophthalmol. 2024;24(1):224. doi: 10.1186/s12886-024-03497-4.
56. Ophir A, Hanna R, Martinez MR. Importance of 3-D image reconstruction of spectral-domain OCT on outcome of grid laser photocoagulation for diffuse diabetic macular edema. Int J Ophthalmol. 2013;6(6):836-843. doi: 10.3980/j.issn.2222-3959.2013.06.17.
57. Stefansson E,Landers, MB 3rd,Wolbarst ML. Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Trans Am Ophthalmol Soc. 1981;79:307-334. PMID: 7200671; PMCID: PMC1312190.
58. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campochiaro PA. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci. 2004;45(2):617–624. doi: 10.1167/iovs.03-0557.
59. Kroll P, Wiegand W, Schmidt J. Vitreopapillary traction in proliferative diabetic vitreoretinopathy. Br J Ophthalmol. 1999;83(3):261-264. doi: 10.1136/bjo.83.3.261.
60. Kashani AH, Zhang Y, Capone A Jr, Drenser KA, Puliafito C, Moshfeghi AA, et al. Impaired retinal perfusion resulting from vitreoretinal traction: A mechanism of retinal vascular insufficiency. Ophthalmol Surg Lasers Imaging Retina. 2016;47(3):1-11. doi: 10.3928/23258160-20160229-03.
61. Adelman R,Parnes AMichalewska Z, Parolini B, Boscher C, Ducournau D. Strategy for the Management of Diabetic Macular Edema: The European Vitreo-Retinal Society Macular Edema Study. BioMed Res Internat. 2015;Article ID352487, http://doi.org/10.1155/2015/352487
62. Browning DJ, Lee C, Stewart MW, Landers III MB. Vitrectomy for center-involved diabetic macular edema. Clin Ophthalmol. 2016 Apr 26;10:735-742. doi: 10.2147/OPTH.S104906
63. Miyamoto N, Ishida K, Ghassemi YK. Restoration of photoreceptor outer segments up to 24 months after pars plana vitrectomy in patients with diabetic macular edema. Ophthalmol Retina. 2017;1(5):389-394.doi.org/10.1016/j.oret.2017.01.017.
64. Kim JH, Kang SW, Ha HS, Kim JR. Vitrectomy combined with intravitreal triamcinolone acetonide injection and macular laser photocoagulation for nontractional diabetic macular edema. Korean J Ophthalmol. 2013;27(3):186-193. http://dx.doi.org/10.3341/kjo.2013.27.3.18661.
65. Hwang S, Kang SW, Kim KT, Noh H, Kim SJ. Three‑year outcomes of vitrectomy combined with intraoperative dexamethasone implantation for non‑tractional refractory diabetic macular edema. Sci Rep. 2021;11(1):1292. https://doi.org/10.1038/s41598-020-80350-w.
66. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99(5):753-759. doi: 10.1016/s0161-6420(92)31901-3.
67. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol. 1996;122(2):258-260. Doi: 10.1016/s0002-9394(14)72018-5.
68. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol. 2000;130(2):178-186. doi: 10.1016/s0002-9394(00)00472-4.
69. Yanyali A, Horozoglu F, Celik E, Ercalik Y, Nohutcu A. Pars plana vitrectomy and removal of the internal limiting membrane in diabetic macular edema unresponsive to grid laser photocoagulation. Eur J Ophthalmol. 2006;16(4):573-581. doi:10.1177/112067210601600412.
70. Landers MB III, Kon Graversen VA, Stewart MW. Early vitrectomy for DME: What makes it a viable treatment? Retinal Physician. 2013;10:56-60.
71. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PA, Beck RW, Bressler NM, et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research network. Retina. 2010;30(9):1488-1495. doi:10.1097/IAE.0b013e3181e7974f.
72. Zhou H, Zhang J , Guo B, Lin J, Mei J, Deng C, et al. Effect of anti-VEGF on early-stage post-vitrectomy macular edema in patients with proliferative diabetic retinopathy. BMC Ophthalmol. 2024;24(1):398. doi: 10.1186/s12886-024-03634-z.
73. Liao M, Huang Y, Wang J, Meng X, Liu Y, Yu J, et al. Long-term outcomes of administration of intravitreal triamcinolone acetonide after posterior vitreous detachment during pars plana vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol. 2023;107(4):560-564. doi: 10.1136/bjophthalmol-2021-320332.
74. Kim J, Kang SW, Shin DH, Kim SJ, Cho GE. Macular ischemia and outcome of vitrectomy for diabetic macular edema. Jpn J Ophthalmol. 2015;59(5):295-304. doi: 10.1007/s10384-015-0402-4.
75. Hatano M, Higashijima F, Yoshimoto T, Ogata T, Ohta M, Kobayashi Y, et al. Evaluation of microaneurysms as predictors of therapeutic response to anti-VEGF therapy in patients with DME. Plos One. 2022;17(11):e0277920. doi:10.1371/journal.pone.0277920.
76. Watanabe A, Takashima H, Nakano T. Effect of microaneurysms on anti-VEGF treatment for diabetic macular edema: A retrospective cross-sectional study. Medicine (Baltimore). 2023;102(44):e35888. doi:10.1097/MD.000000000000035888.
77. Nozaki M, Kato A, Yasukawa T, Suzuki K, Yoshida M, Ogura Y. Indocyanine green angiography-guided focal navigated laser photocoagulation for diabetic macular edema. Jpn J Ophthalmol. 2019;63(3):243–254. doi: 10.1007/s10384-019-00662-x.
78. Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol. 2009;93(10):1341–1344. doi: 10.1136/bjo.2008.146712.
79. Tanaka H, Kojima K, Miyatani T, Kusada N, Terao N, Nagata K, et al. A new surgical approach for the treatment of a refractory foveal microaneurysm: A case report. Am J Ophthalmol Case Rep. 2024 Mar 1;34:102034. doi:10.1016/j.ajoc.2024.102034.
80. Takamura Y, Yamada Y, Morioka M, Gozawa M, Matsumura T, Inatani M. Turnover of Microaneurysms after intravitreal injections of faricimab for diabetic macular edema. Invest Ophthalmol Vis Sci. 2023 Oct 3;64(13):31. doi: 10.1167/iovs.64.13.31.
81. Rush RB. One year results of faricimab for aflibercept-resistant diabetic macular edema. Clin Ophthalmol 2023 Aug 16;17:2397-2403. Doi: 10.2147/OPTH.S424314.
82. Takamura Y, Yamada Y, Inatani M. Role of microaneurysms in the pathogenesis and therapy of diabetic macular edema: A descriptive review. Medicina (Kaunas). 2023;59(3):435. doi: 10/3390/medicina59030435
83. Sawa M, Nakagawa N, Shunto T, Nishiyama I. Two cases of diabetic macular edema with diminished areas of retinal non-perfusion and microaneurysms after intravitreal faricimab injections. Am J Ophthalmol Case Rep. 2023 Dec 7;4;33:101973. doi: 10.1016/j.ajoc.2023.101973.
84. Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU. Diabetic macular edema: What is focal and what is diffuse? Am J Ophthalmol. 2008;146(5):649–655. doi: 10.1016/j.ajo.2008.07.013.
85. Yamada Y, Suzuma K, Ryu M, Tsuiki E, Fujikawa A, Kitaoka T. Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling. Curr Eye Res. 2013;38(12):1261-1265. doi: 10.3109/02713683.2013.820327?